Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Liabilities and Shareholders Equity (2016 - 2025)

Palisade Bio (PALI) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $7.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 25.31% to $7.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $32.7 million, a 33.12% decrease, with the full-year FY2024 number at $10.9 million, down 22.57% from a year prior.
  • Liabilities and Shareholders Equity was $7.0 million for Q3 2025 at Palisade Bio, up from $6.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $18.3 million in Q2 2023 to a low of $6.7 million in Q2 2025.
  • A 5-year average of $12.3 million and a median of $12.8 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 134.31% in 2023, then plummeted 48.2% in 2025.
  • Palisade Bio's Liabilities and Shareholders Equity stood at $16.3 million in 2021, then dropped by 3.14% to $15.8 million in 2022, then fell by 10.85% to $14.1 million in 2023, then decreased by 22.57% to $10.9 million in 2024, then tumbled by 35.91% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Liabilities and Shareholders Equity are $7.0 million (Q3 2025), $6.7 million (Q2 2025), and $8.2 million (Q1 2025).